5/9/2025

Janusmed sex and gender

Janusmed sex and gender – mifepristone

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
B B
B B

Mifepristone

Mifepristone

Class : B

Show all info

Print

Contact us

  1. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999

  2. Mifegyne (mifepriston). Fass.se [www]. [updated 2015-12-10, cited 2017-04-11].

  3. Physicians' Desk Reference. http://www.pdr.net. [cited 2017-04-11].

  4. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317:516-524.

  5. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-49.

  6. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005;84:1719-26.

  7. Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther. 2009;26:959-69.

  8. Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring). 2010;18:2295-300.

  9. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]

  1. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999
  2. Mifegyne (mifepriston). Fass.se [www]. [updated 2015-12-10, cited 2017-04-11].
  3. Physicians' Desk Reference. http://www.pdr.net. [cited 2017-04-11].
  4. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317:516-524.
  5. Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. J Clin Endocrinol Metab. 2012;97:2039-49.
  6. Spitz IM, Grunberg SM, Chabbert-Buffet N, Lindenberg T, Gelber H, Sitruk-Ware R. Management of patients receiving long-term treatment with mifepristone. Fertil Steril. 2005;84:1719-26.
  7. Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK. Mifepristone treatment of olanzapine-induced weight gain in healthy men. Adv Ther. 2009;26:959-69.
  8. Gross C, Blasey CM, Roe RL, Belanoff JK. Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men. Obesity (Silver Spring). 2010;18:2295-300.
  9. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]